Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patientsFinancial support: This study was supported by the NHLBI grant HL61922 (to B.M.C.-F.) and HL65578 (to N.S.K).
13. September 2006
Accepted after resubmission 01. März 2007
24. November 2017 (online)
HaemophiliaA patients treated with human factorVIII (fVIII) may develop antibody (Ab) inhibitors to fVIII. FVIII-specific CD4+ T cells are common in haemophilia A patients, but also in healthy subjects who do not have a sustained anti-fVIII Ab response. Here, we examined the fVIII-induced IFNγ -, IL-4- and TGF- β 1-producing CD4+ T blasts by culturing peripheral blood mononuclear cells (PBMC) from controls and patients with recombinant fVIII. FVIII exposure significantly increased IFNγ - and IL-4-, but not TGF-β 1-producing CD4+ T blasts in patients with inhibitors. Patients without inhibitors had fVIII-induced IFNγ - andTGF-β 1-,but not IL-4-producing CD4+ T blasts.Controls did not have IL-4-producing CD4+ T blasts. However, controls whose PMBC proliferated in response to fVIII had fVIII-induced CD4+ T blasts that produced IFN-γ, the number of which correlated with the intensity of the proliferative response to fVIII of their PMBC, whereas controls whose PMBC did not proliferate to fVIII had predominantly fVIII-induced CD4+ T blasts that producedTGF- β 1.The presence in controls and patients without inhibitors of fVIII-induced IFN-γ -producing CD4 + T cells, but not IL-4-producing CD4+ T cells, which are abundant in inhibitor patients, suggests a role of Th1 cells in initiating the immune response to fVIII, and of Th2 cells in the development of strong inhibitor production. The polarized high ratios of Th3/Th1 and Th3/Th2 in controls and patients without inhibitors suggest that a preponderance ofTh3 cells in the response to fVIII may help to maintain tolerance to fVIII.
- 1 Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 127: 379-391.
- 2 Franchini M, Salvagno GL, Lippi G. Inhibitors in mild/moderate haemophilia A: an update. Thromb Haemost 2006; 96: 113-118.
- 3 Reding MT, Wu HY, Krampf M. et al. Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost 2000; 84: 634-652.
- 4 Singer ST, Addiego JE, Reason DC. et al. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors. Thromb Haemost 1996; 76: 17-22.
- 5 Hu GL, Okita DK, Diethelm-Okita BM. et al. Recognition of coagulation factor VIII by CD4+ T cells of healthy human. J Thromb Haemost 2003; 01: 2159-2166.
- 6 Moreau A, Lacroix-Desmazes S, Stieltjes N. et al. Antibodies to the fVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and normal polyclonal human IgG. Blood 2000; 95: 3435-3441.
- 7 Batlle J, Gomez E, Rendal E. et al. Ab to factor VIII in plasma of patients with hemophilia A and normal subjects. Ann Hematol 1996; 72: 321-326.
- 8 Gilles JGG, Saint-Remy JMR. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J Clin Invest 1994; 94: 1496-1505.
- 9 Murphy KM. T lymphocyte differentiation in the periphery. Curr Opin Immunol 1998; 10: 226-232.
- 10 Santana MA, Rosenstein Y.. What it takes to become an effector T cell: the process, the cells involved, and the mechanisms. J Cell Physiol 2003; 195: 392-401.
- 11 Mills KH. Antigen-specific regulatory T cells-- their induction and role in infection. Semin Immunol 2004; 16: 107-117.
- 12 Maggi E, Cosmi L, Liotta F. et al. Thymic regulatory T cells. Autoimmun Rev 2005; 04: 579-586.
- 13 Weiner HL. Induction and mechanism of action of transforming growth factor- β -secreting Th3 regulatory cells. Immunol Rev 2001; 182: 207-214.
- 14 Lan RY, Ansari AA, Lian ZX. et al. Regulatory T cells: development, function and role in autoimmunity. Autoimmun Rev 2005; 04: 351-363.
- 15 Holzer U, Kwok WW, Nepom GT. et al. Differential antigen sensitivity and costimulatory requirements in human Th1 and Th2 antigen-specific CD4+ cells with similar TCR avidity. J Immunol 2003; 170: 1218-1223.
- 16 Valentini G, Baroni A, Esposito K. et al. Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation. J Clin Immunol 2001; 21: 210-217.
- 17 Reding MT, Lei S, Lei H. et al. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost 2002; 88: 568-575.
- 18 Perez-Machadol MA, Ashwoodl P, Thomson MA. et al. Reduced transforming growth factor- β 1-producing T cells in the duodenal mucosa of children with food allergy. Eur J Immunol 2003; 33: 2307-2315.
- 19 Chatenoud L, Bach LP. Adaptive human regulatory T cells: myth or reality?. J Clin Invest 2006; 116: 2325-2327.
- 20 Kitani A, Chua K, Nakamura K. et al. Activated self-MHC-reactive T cells have the cytokine phenotype of Th3/T regulatory cell 1 T cells. J Immunol 2000; 165: 691-70.
- 21 Kim YK, Myint AM, Lee BH. et al. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 1129-1134.
- 22 Akbari O, Stock P, DeKruyff RH. et al. Role of regulatory T cells in allergy and asthma. Curr Opin Immunol 2003; 15: 627-633.
- 23 Abbas A, Murphy K, Sher A.. Functional diversity of helper T cell lymphocytes. Nature 1996; 383: 787-793.
- 24 Seder RA, Paul WE. Acquisition of lymphokineproducing phenotype by CD4+ T cells. Ann Rev Immunol 1994; 12: 635-673.
- 25 Gilles JGG, Jacquemin MG, Saint-Remy JMR. Factor VIII inhibitors. Thromb Haemost 1997; 78: 641-646.
- 26 Fulcher CA, de Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987; 69: 1475-1480.
- 27 Wu H, Reding M, Qian J. et al. Mechanism of the immune response to human factor VIII in murine hemophilia A. Thromb Haemost 2001; 85: 125-133.
- 28 Bril WS, van Helden PM, Hausl C. et al. Tolerance to factor VIII in a transgenic mouse expressing human factor VIII cDNA carrying an Arg(593) to Cys substitution. Thromb Haemost 2006; 95: 341-347.
- 29 Reipert BM, Ahmad RU, Turecek PL. et al. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A. Thromb Haemost 2000; 84: 826-832.
- 30 Gomes JAS, Bahia-Oliveira LMG, Rocha MOC. et al. Evidence that development of severe cardiomyopathy in human Chagas’disease is due to a Th1-specific immune response. Infect Immun 2003; 71: 1185-1193.
- 31 Seder RA, Marth T, Sieve MC. et al. Factors involved in the differentiation of TGF- β -producing cells from naive CD4+ T cells: IL-4 and IFN-γ have opposing effects, while TGF- β positively regulates its own production. J Immunol 1998; 160: 5719-5728.
- 32 Pala P, Hussell T, Openshaw PJM. Flow cytometric measurement of intracellular cytokines. J Immunol Methods 2000; 243: 107-124.
- 33 Cao O, Armstrong E, Schlachterman A. et al. Immune deviation by mucosal antigen administration suppresses gene-transfer-induced inhibitor formation to factor IX. Blood 2006; 108: 480-486.
- 34 Im SH, Barchan D, Souroujon MC. et al. Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis. J Immunol 2000; 165: 3599-3605.
- 35 Miller A, Shapiro S, Gershtein R. et al. Treatment of multiple sclerosis with Copolymer-1: implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998; 92: 113-121.
- 36 Sprent J, Surh CD. T cell memory. Ann Rev Immunol 2002; 20: 551-579.
- 37 Constant S L, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approach. Ann Rev Immunol 1997; 15: 297-332.